RJA
ADAP

Raymond James & Associates’s Adaptimmune Therapeutics ADAP Stock Holding History

Raymond James & Associates’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,218
Closed -$9.96K – 3991
2024
Q2 		$9.96K Buy
+10,218
New +$11.2K ﹤0.01% 3929
2024
Q1 		– Sell
-10,218
Closed -$8.1K – 3914
2023
Q4 		$8.1K Sell
10,218
-151
-1% -$85 ﹤0.01% 3808
2023
Q3 		$8.09K Sell
10,369
-80
-0.8% -$67 ﹤0.01% 3770
2023
Q2 		$9.66K Sell
10,449
-849
-8% -$1.01K ﹤0.01% 3810
2023
Q1 		$12.3K Buy
11,298
+1,250
+12% +$1.94K ﹤0.01% 3830
2022
Q4 		$14.7K Sell
10,048
-525
-5% -$850 ﹤0.01% 3825
2022
Q3 		$11K Hold
10,573
– – ﹤0.01% 3850
2022
Q2 		$18K Hold
10,573
– – ﹤0.01% 3882
2022
Q1 		$22K Buy
+10,573
New +$28.5K ﹤0.01% 3991
2020
Q3 		– Sell
-10,401
Closed -$104K – 3585
2020
Q2 		$104K Sell
10,401
-10,400
-50% -$65.3K ﹤0.01% 3277
2020
Q1 		$57K Sell
20,801
-8,610
-29% -$28.6K ﹤0.01% 3302
2019
Q4 		$35K Buy
29,411
+3,546
+14% +$3.78K ﹤0.01% 3577
2019
Q3 		$39K Buy
25,865
+3,730
+17% +$8.72K ﹤0.01% 3490
2019
Q2 		$89K Sell
22,135
-8,050
-27% -$32.8K ﹤0.01% 3429
2019
Q1 		$130K Buy
30,185
+7,279
+32% +$33.9K ﹤0.01% 3339
2018
Q4 		$132K Buy
22,906
+8,498
+59% +$62.7K ﹤0.01% 3254
2018
Q3 		$195K Sell
14,408
-1,188
-8% -$12.5K ﹤0.01% 3300
2018
Q2 		$185K Sell
15,596
-9,544
-38% -$119K ﹤0.01% 3283
2018
Q1 		$282K Buy
25,140
+8,056
+47% +$70.5K ﹤0.01% 2920
2017
Q4 		$114K Buy
+17,084
New +$132K ﹤0.01% 3186

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Raymond James & Associates's ADAP Position: Q3 2024 in Review

Raymond James & Associates sold out of Adaptimmune Therapeutics (ADAP) in Q3 2024, closing a stake of 10,218 shares — an estimated $9.96K sold.

Raymond James & Associates first reported a position in ADAP in Q4 2017 and held it in 20 quarters. The position peaked at $282K in Q1 2018. 81 funds tracked by Wall St. Rank hold ADAP as of Q3 2024.

  • Raymond James & Associates reported no remaining Adaptimmune Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Raymond James & Associates sold 10,218 Adaptimmune Therapeutics shares in Q3 2024, an estimated $9.96K.
  • Raymond James & Associates first reported a position in Adaptimmune Therapeutics in Q4 2017 and held it in 20 quarters.
  • Raymond James & Associates's Adaptimmune Therapeutics position peaked at $282K in Q1 2018.
  • 81 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.